Discover open access scientific publications

Search, annotate, share and cite publications

Publications by John C. Byrd

Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101

Journal of Clinical Oncology

English

Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein

Journal of Clinical Oncology

English

Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician

Journal of Clinical Oncology

English

PLK1: A Promising and Previously Unexplored Target in Double-Hit Lymphoma

Journal of Clinical Investigation

Medicine

2018

English

Next Generation XPO1 Inhibitor Shows Improved Efficacy and in Vivo Tolerability in Hematologic Malignancies

English

TCL1targetingmiR-3676is Codeleted With Tumor Protein P53 in Chronic Lymphocytic Leukemia

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

2015

English

Long-Term Follow-Up of the RESONATE™ Phase 3 Trial of Ibrutinib Versus Ofatumumab

English

Non-Hodgkin's Lymphomas

Journal of the National Comprehensive Cancer Network : JNCCN

Medicine

Oncology

2011

English

Targeting PI3Kδ Function for Amelioration of Murine Chronic Graft-Versus-Host Disease

American Journal of Transplantation

English

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by John C. Byrd

Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101

Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein

Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician

PLK1: A Promising and Previously Unexplored Target in Double-Hit Lymphoma

Next Generation XPO1 Inhibitor Shows Improved Efficacy and in Vivo Tolerability in Hematologic Malignancies

TCL1targetingmiR-3676is Codeleted With Tumor Protein P53 in Chronic Lymphocytic Leukemia

Long-Term Follow-Up of the RESONATE™ Phase 3 Trial of Ibrutinib Versus Ofatumumab

Non-Hodgkin's Lymphomas

Targeting PI3Kδ Function for Amelioration of Murine Chronic Graft-Versus-Host Disease

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma